MedMira Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- MedMira Inc. develops, manufactures and markets rapid diagnostic tests and technology platforms based on its patented Rapid Vertical Flow (RVF) technology for point-of-care detection of infectious diseases including HIV, hepatitis B and C, syphilis and other sexually transmitted infections; its core commercialized products comprise Reveal G4 HIV-1/2 tests, Multiplo multiplex combination tests for HIV-1/2, hepatitis B and C, and syphilis, Miriad research toolkits for developing new diagnostics, and RevealCOVID-19 tests. The company provides these solutions to hospitals, clinics, laboratories, public health agencies, governments and individual users through a global network of medical distributors and strategic partners, with primary operations in North America including the United States and Canada, and sales extending to Europe, China and other international markets. Founded in 1993 and headquartered at 155 Chain Lake Drive, Halifax, Nova Scotia, Canada, MedMira operates manufacturing facilities in Halifax and maintains a sales and customer service office in Atlanta, Georgia, United States; MedMira Holding AG serves as its controlling shareholder. In fiscal 2025, the company achieved key U.S. regulatory milestones including VA and Federal listings to access multi-year government contracts, expanded its distribution network with specialized partners targeting VA, Federal and state opportunities, advanced clinical trials toward an anticipated FDA CLIA waiver for its Reveal G4 HIV test to broaden point-of-care market access, secured full funding through a partnership with REACH Nexus at St. Michael's Hospital's MAP Centre for clinical trials in Canada, and progressed development of a commercial AI-enhanced diagnostic prototype via a strategic technology alliance with MiROQ to accelerate market entry and expand product offerings.
MedMira Reports Second Quarter Results FY2025
MedMira Reports First Quarter Results FY2026
MedMira Reports FY2025 Fourth Quarter and Year End Financial Results
Health Canada Approves MedMira's Reveal(R) Rapid TP Test - Urgent New Tool In The Battle Against Syphilis
MedMira Announces Launch of Clinical Trial for Its Multiplo(R) TP/HIV Self-Test in Canada
MedMira Reports Second Quarter Results FY2025
MedMira Inc. and Lovell Announce Partnership to Increase Access to Reveal(R) G4 HIV-1/2 rapid test for VA, Department of Defense
MedMira Reports Second Quarter Results FY2025
MedMira Announces Partnership with MediGroup Physician Services in the United States
MedMira Announces Exclusive Distribution Agreement with Trimedic Inc. for Canada
MedMira Receives Investigational Testing Authorizations for Multiplo(R) TP/HIV Self-Test and Non-Professional Use Applications
MedMira Receives Health Canada Approval for Its Reveal(R) G4 Rapid HIV-1/2 Test for Point-of-Care Use
MedMira Receives Investigational Testing Authorization for its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test
MedMira Reports First Quarter Results FY2025
MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV
MedMira Reports FY2024 Fourth Quarter and Year End Financial Results
MedMira Announces the appointment of Vice President of Commercial Operations
MedMira Reports Third Quarter Results FY2024
MedMira Announces the Hire of Vice President of Business Development
MedMira Reports Second Quarter Results FY2024